Now live: Pro — the full 13F research suite for serious investorsSee pricing →
a16z Capital Management, L.L.C.

Q1 2025 · 13F-HR

a16z Capital Management, L.L.C.holdings as filed

Filed 2025-05-15 · accession 0001415889-25-013091

$700.9M
Reported value
13
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
25809K105DASHDOORDASH INC$291.9M41.6%1,597,010CommonSOLE
79589L106IOTSAMSARA INC$153.2M21.9%3,995,652CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$97.2M13.9%2,748,523CommonSOLE
852234103XYZBLOCK INC$55.2M7.88%1,016,697CommonSOLE
00437E102ACCDUSDACCOLADE INC$37.7M5.38%5,398,708CommonSOLE
578784100MAZEMAZE THERAPEUTICS INC$18.7M2.67%1,702,225CommonSOLE
63909J108NAUTNAUTILUS BIOTECHNOLOGY INC$15.2M2.17%17,653,917CommonSOLE
09077V100BIOABIOAGE LABS INC$12.2M1.73%3,233,170CommonSOLE
13463J101CAMPCAMP4 THERAPEUTICS CORP$8.5M1.21%2,125,339CommonSOLE
683712103OPENOPENDOOR TECHNOLOGIES INC$6.3M0.90%6,200,821CommonSOLE
29479A108ERASERASCA INC$3.9M0.56%2,862,500CommonSOLE
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$618,8380.09%108,568CommonSOLE
23257B305CYNCYNGN INC$260,8560.04%57,584CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.